During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Marc Braunstein, NYU Langone Health, New York, US, and Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University, Paris, FR, about the role of upfront transplant consolidation in the era of novel agents.

Long-term follow-up data about upfront autologous hematopoietic stem cell transplantation (auto-HSCT) were presented at the 62nd ASH Annual Meeting and Exposition. Mohty and Braunstein agree on the importance of auto-HSCT and on the fact that, when possible, it should not be delayed.

They outline the value of upfront auto-HSCT even in the era of novel agents being developed for multiple myeloma. They also talk about consolidation and maintenance therapy after transplant.

Hosted on Acast. See acast.com/privacy for more information.